Create your personal agenda –check the favourite icon
Roundtables
Keynotes
Public policy and the patient voice in defining market access solutions
Sue O'Leary, Vice President, Global Market Access, Prime Global
Roundtable 1: Payer insights and engagement for BeneLux
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, NIHDI - INAMI Belgium
Roundtable 2: HTA insights and engagement for Italy
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Roundtable 3: A tale of two diseases: how orphan drugs can navigate NICE
Josie Godfrey, Director, JG Zebra Consulting
Roundtable 4: Achieving greater appeal for Value Based Agreements
Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh
Roundtable 5: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Roundtable 6: Accelerating access to treatments for rare diseases
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Roundtable 7: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter, Partner, Viopas Partners
Roundtable 8: Exploring Digital Therapeutics
Olaf Schoeman, Head Of Operations And Director, Pharmerit International
Chair’s Opening remarks
Evidence & Value
Chair’s Opening remarks
Rare Diseases, Big Data, Diagnostics & Digital
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Chair’s Opening remarks
Managed Entry Agreements, HTA & Advanced Therapies
Andrea Mantovani, Former Market Access Executive, Independent
Chair’s Opening remarks
Affordability & Far East
Christina Vandoros, Director, Macroeconomics And Health Policy - Emea, Janssen
Delivering Value Effectively: A German perspective
Evidence & Value
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Big data & AI in pricing and access to medicines
Rare Diseases, Big Data, Diagnostics & Digital
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Experiences from managed entry agreements
Managed Entry Agreements, HTA & Advanced Therapies
Bart Van Den Daele, Head Of External Affairs - Director Market Access, Gilead Sciences
Political dimensions affecting affordability in the Dutch market
Affordability & Far East
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Exploring value-added medicines
Evidence & Value
Maja Sercic, Policy & Science Manager, Medicines for Europe
Optimal Global Pricing: Resolving with exact numerical solutions two problems - Optimal Launch Pricing and Parallel Trade
Rare Diseases, Big Data, Diagnostics & Digital
Mitch Scurtu, President, Global Technologies
Exploring the use of Managed Entry Agreements in the Middle East
Managed Entry Agreements, HTA & Advanced Therapies
Camille Harfouche, Rare Diseases and Access Lead, Algorithm
Solving the Affordability Challenge – what pharma companies can do beyond philanthropy
Affordability & Far East
John Alter, Vice President Pricing And Market Access, Pfizer
Value considerations in Canada’s new regulatory pricing framework
Evidence & Value
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
How transparency in R&D can improve access conditions?
Rare Diseases, Big Data, Diagnostics & Digital
Jaume Vidal, Senior Policy Advisor-European Projects, Health Action International
Interview: What to watch out for in implementing managed entry agreements
Managed Entry Agreements, HTA & Advanced Therapies
Shanthy Krishnaraja, Senior Director, Market Access And Strategy, Seqirus
Roundtables
Keynotes
Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie
Roundtable 2: Access and HTA considerations for Turkey and Ukraine
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Kagan Atikeler, Researcher, Utrecht University
Roundtable 3: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster, Head Market Access, Santhera Pharmaceuticals
Roundtable 4: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
Roundtable 5: Exploring innovative reimbursement and payment models for orphan drugs
Jaime Espin, Professor, Andalusian School Of Public Health
Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc
Roundtable 6: Market Access and pricing considerations for Spain
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Jonathan Galduf, Head Of Market Access & Public Affairs, CSL Behring
Roundtable 7: How do you include the patient perspective in a outcomes-based contract?
Girisha Fernando, CEO, Lyfegen HealthTech AG
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Roundtable 8: Perspectives on remote project delivery for global pricing and market access functions: operational aspects and life hacks that ensure market access continuity
James Wright, Director, Valid Insight
Frank Cousins, Senior Director, Valid Insight
Chair’s remarks
Evidence & Value
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Sandro Cesaro-Tadic, Head Pricing I8 And Product Pricing Strategies, Roche
Chair’s remarks
Managed Entry Agreements, HTA & Advanced Therapies
Meindert Boysen, Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Chair’s remarks
Biosimilars, Value Added Medicines & Emerging Markets
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
What does value mean for LMIC countries?
Evidence & Value
Rabia Kahveci, Senior Technical Advisor on Pharmaceutical Policies and Governance, Management Sciences for Health
From Digital To Big Data Analytics & AI In Real World Data
Rare Diseases, Big Data, Diagnostics & Digital
Igor Rudychev, Head of Analytics, Novartis
Exploring payer and implementation considerations for managed entry agreements
Managed Entry Agreements, HTA & Advanced Therapies
Bertrand Tardivel, General Manager, Frehel GmbH
Sustainable market competition for long-term value generation of biosimilar medicines
Biosimilars, Value Added Medicines & Emerging Markets
Diogo Piedade, Market Access Manager, Medicines for Europe
Gene therapies: Beyond a one and done
Evidence & Value
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Access and pricing considerations in the world of innovative diagnostics
Rare Diseases, Big Data, Diagnostics & Digital
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Achieving the best outcomes when negotiating managed entry agreements
Managed Entry Agreements, HTA & Advanced Therapies
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.
Market access for value added medicines in Europe
Biosimilars, Value Added Medicines & Emerging Markets
Olga Diachenko, Market Access Manager Europe, Accord Healthcare
What does value mean for a private payer?
Evidence & Value
Charles De Cidrac, Director Of Health Insurance, AXA
Diabetes care in the world of digital health: What does the evidence suggest?
Rare Diseases, Big Data, Diagnostics & Digital
The patient perspective in managed entry agreements
Managed Entry Agreements, HTA & Advanced Therapies
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
A look at legislation for Biosimilars in Germany
Biosimilars, Value Added Medicines & Emerging Markets
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Chair’s remarks
Pricing and Market Access & Government Affairs
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Chris Wasden, Head of HappifyDTx, Happify Health
Chair’s remarks
Patient Advocacy & Payer Engagement
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Chair’s remarks
Contracting, Price Tendering & Payer Communications
Diar Fattah, Global Director, Innovative Value Strategies And Evidence (Respiratory), AstraZeneca
New developments in Poland for pricing & reimbursement
Pricing and Market Access & Government Affairs
Marcin Czech, Former Vice Minister, Ministry of Health Poland
Digital Medicines: Where are we now and what next
Rare Diseases, Big Data, Diagnostics & Digital
Oliver Gassner, Head G4A Digital Health Intelligence Emea, Bayer
Interview: The Importance of patient advocacy and the challenge of financial toxicity
Patient Advocacy & Payer Engagement
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Hyatt DeGreen, President, LANCASTER CANCER CENTER
Opportunities of regional and national contracting in Germany
Contracting, Price Tendering & Payer Communications
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Governmental policy in the healthcare industry across the Middle East
Pricing and Market Access & Government Affairs
Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie
Interview: Creating an evidence strategy from the perspective of a digital therapeutic start-up
Rare Diseases, Big Data, Diagnostics & Digital
Sven Jungmann, Co-Founder, FoundersLane
Industry and patients working together for better access
Patient Advocacy & Payer Engagement
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
How to build and communicate a convincing customer value proposition in tendering
Contracting, Price Tendering & Payer Communications
Nico Bacharidis, Former Global Tender Lead And Founder Of Growpal, Pfizer
Insight into US Government Policy and Payer strategy
Pricing and Market Access & Government Affairs
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Using a digital pricing and market access simulator App to enhance product development
Rare Diseases, Big Data, Diagnostics & Digital
Raf De Wilde, Senior Executive Advisor, Valid Insight
The value provided to pharma through patient advocacy – hard lessons learnt from industry
Patient Advocacy & Payer Engagement
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
Multi-, Cross-, Omni-Channel Evolution in Payer Communications
Contracting, Price Tendering & Payer Communications
Stephanie Chen, Associate Director, Global Access Marketing Oncology, Bayer
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Innovation in industry and practical considerations for biotechs
Keynotes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Trends in modelling approaches for successful reimbursement of ATMPs
Keynotes
Ion Agirrezabal, Senior Consultant, Covance Market Access And Phase Iv Solutions, Covance Market Access
Interview: Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value
Keynotes
Dr Bharat Tewarie, Founder & CEO Boston BioPharma Consultants/ Former EVP& Chief Marketing Officer, UCB
Around the world in 80 MEAs
Keynotes
Ezequiel Heredia, Consultant, Lifescience Dynamics Ltd
Embracing competition to deliver the true value of biosimilars
Keynotes
Isabell Remus, Head Biopharmaceuticals Europe, Sandoz
Roundtables
Keynotes
Roundtable 10: Branded combo-pricing: Where too next?
Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer
Roundtable 11: New HTA requirements in France: impact of unmet need on access
Delphine Houzelot, VP Market Access, Prioritis Market Access
Roundtable 1: Open
Roundtable 2: Pricing Strategy – What to Do and When?
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Roundtable 3: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan, Global Market Access - Health Systems Strategy, Value Recognition, Roche
Roundtable 4: Challenges associated with communicating the value of Cell & Gene Therapies
Roundtable 5: HTA developments across Eastern Europe
Tatyana Benisheva, Professor In Drug Regulatory Affairs, Bulgarian Association For Drug Information
Roundtable 6: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Roundtable 7: Patient based generated evidence
Caridad Pontes, Manager Of Pharmacotherapeutic Harmonization, Catalan Health Service
David Elvira, Heads Eu Public Affairs, Sanofi
Roundtable 8: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Jost Leemhuis, Head Of Safety Science, Roche
Roundtable 9: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Chair’s Remarks
Keynotes
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, Head Of Pricing And Access Capabilities, Emerging Marke, GlaxoSmithKline
Interview: Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement
Keynotes
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Virtual Research: What it Is & What it’s Doing in the Real-World Setting
Keynotes
Interview: Reflections on Medical Innovations in the time of COVID-19 Pandemic
Keynotes
Ryan Saadi, CEO, Tevogen Bio
Chair’s remarks
Evidence & Value
Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie
Chair’s remarks
Pricing and Market Access & Government Affairs
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Chair’s remarks
Managed Entry Agreements, HTA & Advanced Therapies
Reg Waldeck, Oncology Market Access Strategy Leader, Bayer Corp
Chair’s remarks
Affordability & Far East
Mark Chalmers, Director, Navigant – A Guidehouse Company
Can Pharma save $1 billion through the strategic use of RWE?
Evidence & Value
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Lessons learnt in implementing an outcomes based contract
Pricing and Market Access & Government Affairs
Diar Fattah, Global Director, Innovative Value Strategies And Evidence (Respiratory), AstraZeneca
Patient access to rare disease treatments: Insights from industry
Rare Diseases, Big Data, Diagnostics & Digital
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Horizon scanning in the HTA process; helping to facilitate UK market access
Managed Entry Agreements, HTA & Advanced Therapies
Dapo Ogunbayo, Programme Manager - Healthcare Innovations (Pharmaceuticals), NIHR Innovation Observatory, Newcastle University
Market access conditions and healthcare for the Far East and Australasia
Affordability & Far East
Diane Munch, Vice President, Global Pricing, Patient And Health Impact, Pfizer
Samuel Taylor, Emerging Markets Pricing Lead, Pfizer
RWE for regulatory and HTA decision-making: latest precedent and what's ahead
Evidence & Value
Ashley Jaksa, VP Analytic Solutions, Aetion, Inc.
Outcome-Based contracts and other innovative pricing models: Expectation or reality?
Pricing and Market Access & Government Affairs
Patient Access for Rare Disease – A HTA Perspective
Rare Diseases, Big Data, Diagnostics & Digital
Ruth Howells, Practice Leader, VP, Clarivate Analytics
EUnetHTA Joint Assessments and Implications for the Industry
Managed Entry Agreements, HTA & Advanced Therapies
Breaking down the ‘Great Wall’: do the evolving market access policy dynamics in China represent the next big opportunity of Pharma?
Affordability & Far East
Amy Wang, Managing Consultant, Navigant – A Guidehouse Company
Effective RWE strategy for regulatory approval and reimbursement
Evidence & Value
Nneka Onwudiwe, Founder And Chief Executive Officer, Pharmaceutical Economics Consultants of America (PECA) LLC
Interview: Value-based Contracting Status and Outlook
Pricing and Market Access & Government Affairs
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
The continuing changing landscape in creating value beyond price for rare disease products in the US
Rare Diseases, Big Data, Diagnostics & Digital
Diann Potestio, Vice President Market Access, Ascendis Pharma
Insight on HTA in Ukraine
Managed Entry Agreements, HTA & Advanced Therapies
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Bringing accessibility and affordability to scale in the next decade
Affordability & Far East
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Chair’s remarks
Evidence & Value
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Chair’s remarks
Pricing and Market Access & Government Affairs
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Chair’s remarks
Managed Entry Agreements, HTA & Advanced Therapies
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Chair’s remarks
Biosimilars, Value Added Medicines & Emerging Markets
Kevin Loth, Former Vice President, Corporate Affairs And Policy, Worldwide Markets, Celgene
Use of RWE in oncology
Evidence & Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Market access for gene therapies in Germany
Pricing and Market Access & Government Affairs
Axel Boehnke, Director Market Access Eu North, PTC Therapeutics
The impact of COVID-19 on funding for rare disease research
Rare Diseases, Big Data, Diagnostics & Digital
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Understanding and engaging with HTA in Russia
Managed Entry Agreements, HTA & Advanced Therapies
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Challenges for reimbursement and innovation in Latin
Biosimilars, Value Added Medicines & Emerging Markets
Giovanny Leon, P&Ma Director, Novartis AG
Integrating evidence effectively into a viable commercial strategy
Evidence & Value
Ali Ciger, Commercial Director, Pain, Pfizer
Future Trends - How Payers in the US and Europe are adapting to the ATMP revolution
Pricing and Market Access & Government Affairs
Herve Lilliu, Chief Executive Officer, inbeeo
Innovative reimbursement and payment models for orphan drugs
Rare Diseases, Big Data, Diagnostics & Digital
Jaime Espin, Professor, Andalusian School Of Public Health
Understanding risk-sharing agreements and post-reimbursement evaluation in South Korea
Managed Entry Agreements, HTA & Advanced Therapies
Jeonghoon Ahn, Former Director, National Evidence-based Healthcare Collaborating Agency
Exploring commercial strategies in orphan drugs in the public healthcare system in Argentina
Biosimilars, Value Added Medicines & Emerging Markets
Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics
Latest developments in evidence for oncology
Evidence & Value
Reg Waldeck, Oncology Market Access Strategy Leader, Bayer Corp
Adopting a patient centric approach to access for gene therapies
Pricing and Market Access & Government Affairs
Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
Joint assessment for orphan drugs: Insight from EUnetHTA
Rare Diseases, Big Data, Diagnostics & Digital
Anne Willemsen, Project Manager Eunethta, Zorginstituut Nederland / EUnetHTA
The DIVE framework: how to incorporate all information into your estimation process: Direct evidence, Indirect evidence, validation and external information incorporation?
Managed Entry Agreements, HTA & Advanced Therapies
Mario Ouwens, Senior Statistical Science Director, Astra Zeneca
The link between HTA and decision-making in resource allocation
Biosimilars, Value Added Medicines & Emerging Markets
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Roundtables
Keynotes
Roundtable 10: Capability building for RWE
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Roundtable 12: Virtual approaches for real-world research
Roundtable 1: HTA: to collaborate or not? Secrets of partnering success
Akshay Kumar, Partner, Partners4Access
Francesca Cook, Senior Director, Global Head Of Pricing And Market Access, Regenxbio
Roundtable 2: Developments in pricing and patient access for speciality treatments
Jenny Ebert, National Account Director, Ascendis Pharma
Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals
Roundtable 3: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Roundtable 4: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther, General Manager, EVERSANA
Roundtable 5: Innovative and Value Based Agreements – more of the same, or solution for access?
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Roundtable 6: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich, Managing Director, Plich Advisory
Roundtable 7: Exploring access and pricing challenges for low to middle income countries
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Giovanny Leon, P&Ma Director, Novartis AG
Roundtable 8: Access and pricing considerations for CAR-T development
Nuno Prego Ramos, Chief Executive Officer, Cellmabs
Roundtable 9: The use of real-world evidence to support outcomes-based pricing and reimbursement decisions: opportunities and challenges
Dimitrios Tsourougiannis, Senior Hemar Manager, Janssen - Cilag Ltd
Ahmed Elsada, Health Economics, Market Access and Reimbursement Manager, Janssen
USA and International Reference Pricing – what will happen to confidential discounts in Europe?
Daniel Suhr, Chief Executive Officer, Two Scenarios
Chair’s remarks
Evidence & Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Chair’s remarks
Pricing and Market Access & Government Affairs
Anastasiya Stepanova, GR Manager, S.T.A.D.A.
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Josie Godfrey, Director, JG Zebra Consulting
Chair’s remarks
Patient Advocacy & Payer Engagement
Kart Veliste, Chief Specialist At Department Of Medicines And Medical Devices, Haigekassa Estonia
Chair’s remarks
Biosimilars, Value Added Medicines & Emerging Markets
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, Head Of Pricing And Access Capabilities, Emerging Marke, GlaxoSmithKline
Insights into the implementation of HTA recommendations: Understanding the evidence
Evidence & Value
Belen Corbacho, Health Economist, University of York
The Swedish market: Supporting regional payers in managed introduction and prioritisation of new drug therapies
Pricing and Market Access & Government Affairs
Looking at the role of patient advocacy in pricing policies
Rare Diseases, Big Data, Diagnostics & Digital
Francois Houyez, Treatment Information And Access Director, Health Policy Advisor, EURORDIS
Interview: Policy and the Pandemic: Biopharmaceutical Policy and Legislative Priorities in Addressing Innovation, Pricing, Spending and Affordability, Past, Present and Future
Patient Advocacy & Payer Engagement
Robert Popovian, Vice President Of Government Relations, Pfizer
Market access and pricing conditions across the Middle East and Africa
Biosimilars, Value Added Medicines & Emerging Markets
Ayman Semaan, Market Access, Algorithm
Evidence generation across different therapeutic areas
Evidence & Value
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Developments in Canadian Pharmaceutical Pricing and Market Access
Pricing and Market Access & Government Affairs
Value Based Healthcare: delivering value to hemophilic patients
Rare Diseases, Big Data, Diagnostics & Digital
Lara Pippo, Head Of Market Access, CSL Behring
Understanding the payer assessment process in Norway
Patient Advocacy & Payer Engagement
Einar Andreassen, Head of unit, HTA and Reimbursement, Norwegian Medicines Agency
Pharmaceutical Pricing Policy and Access in South Africa, A Funder’s Perspective – Key Focus on Rare Diseases
Biosimilars, Value Added Medicines & Emerging Markets
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Noluthando Nematswerani, Head - Centre For Clinical Excellence, Discovery Health
Looking at the evidence after launch: addressing access hurdles across different markets
Evidence & Value
Rasmus Jensen, Global Head Of Market Access, Camurus
Market access developments for Russia
Pricing and Market Access & Government Affairs
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Valentin Dodonov, Deputy General Head Of Market Access, BIOCAD
The Hercules Project: Patient-led Access in Rare Diseases
Rare Diseases, Big Data, Diagnostics & Digital
Josie Godfrey, Director, JG Zebra Consulting
What is the value of the patient’s perspective when negotiating with payers?
Patient Advocacy & Payer Engagement
Andrea Mantovani, Former Market Access Executive, Independent
The Sanofi Espoir Foundation- improving access in Africa
Biosimilars, Value Added Medicines & Emerging Markets
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Market Access considerations from NICE
Keynotes
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Trends in HTA Decisions for Oncology, Single & Combination Therapies
Keynotes
Alan Crowther, General Manager, EVERSANA
Magdi Stino, Product Manager, EVERSANA
Achieving greater stakeholder engagement to improve patient and payer related outcomes
Keynotes
What key initiatives are helping to improve cooperation among payers, patients and manufacturers?What innovation is taking place in contracting?What suggestions would you offer to streamline contracting arrangements and improve patient & payer outcomes?
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Ulf Staginnus, Senior Vice President, Head Of Global Market Access And Pricing, Ipsen Pharma
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Evert Jan Van Lente, Director Eu-Affairs, AOK Bundesverdand
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Roundtables
Keynotes
Roundtable 1: Innovation in Contracting
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Roundtable 2: Risk-sharing arrangements: Are they improving patient access to new medicines?
Catarina Lopes Pereira, Global Market Access Manager, Medac
Roundtable 3: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert, Advisor, Independent
Roundtable 4: How to establish a market access department from scratch?
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Roundtable 5: Evidence solutions and CAR-T
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Roundtable 6: Exploring the international reference pricing landscape
Tanya Aiden, Global Products Lead, BIOCAD
Roundtable 7: Market access, Pricing, Payer & HTA developments for the Nordic Region
Einar Andreassen, Head of unit, HTA and Reimbursement, Norwegian Medicines Agency
Dorthe Bartels, Strategic Adviser, Amgros
Roundtable 8: Real world data and its utility in HTA decisions
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Roundtable 9: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell, Director Market Access UK, Shionogi Ltd
Chair’s remarks
Evidence & Value
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Chair’s remarks
Pricing and Market Access & Government Affairs
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Ines Alves, President, ANDO Portugal
Chair’s remarks
Managed Entry Agreements, HTA & Advanced Therapies
Bertrand Tardivel, General Manager, Frehel GmbH
Real world evidence in the era of COVID-19: Reflections from Russia
Evidence & Value
Anastasiya Stepanova, GR Manager, S.T.A.D.A.
Governance in the world of access and pricing
Pricing and Market Access & Government Affairs
Claudia Neuber, Head Of Global Pricing Implementation, AstraZeneca
Innovation in treating rare diseases: HTA approach in Scotland
Rare Diseases, Big Data, Diagnostics & Digital
Mark Macgregor, Medical Director, Golden Jubilee National Hospital
Understanding the advanced therapy landscape and beyond: an investors perspective
Managed Entry Agreements, HTA & Advanced Therapies
Michael Schroter, Partner, Viopas Partners
Value Evidence Generation in Product Lifecycle Management of Medical Technologies: Fit for Purpose, Fit for Future?
Evidence & Value
Luqman Tariq, Market Access Director, Europe, Stryker Corp
Exploring the development of international reference pricing across different jurisdictions
Pricing and Market Access & Government Affairs
Matt Slabbert, Chief Coordinator – Patient Access Policy & UHC, Bayer Pharmaceuticals
Cross indication pricing considerations for gene therapy
Managed Entry Agreements, HTA & Advanced Therapies
Alex Grosvenor, Senior Vice President, PRECISIONadvisors
Early Access to treatment for Rare Disease patients
Rare Diseases, Big Data, Diagnostics & Digital
Rute Fernandes, Head Of Rare Diseases Of Europe And Canada, Takeda
The use of RWE in patient support programs
Evidence & Value
Priyal Sheth, Neuroscientist & VP of Business Development, Q1.6
US insights: Alternative payment methodologies
Pricing and Market Access & Government Affairs
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Exploring repurposed products for rare diseases
Rare Diseases, Big Data, Diagnostics & Digital
Amer Omar, Senior Director, Lupin
Risk sharing agreements for cell and gene therapies
Managed Entry Agreements, HTA & Advanced Therapies
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Roundtables
Keynotes
Roundtable 1: Accelerating Access to treatments for Rare Diseases
Gina Ewy, Head Of Global Market Access, Hansa Biopharma
Roundtable 2: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan, Head - Health Technology Assessment, Discovery Health
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Roundtable 3: Opportunities & Challenges for Collection of RWD in Early Access Programs (EAPs)
Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health
Roundtable 4: Industry and patients working together for better access
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Roundtable 5: Modelling the value of digital health innovations
Roundtable 6: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther, General Manager, EVERSANA
Roundtable 7: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Roundtable 8: Understanding Business Challenges of Shifting IV drugs to SC to Enable Self-delivery
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Alfred Harvey, Associate Director, Health Economics And Outcomes Research, Becton Dickinson
Roundtable 9: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.
Chair’s remarks
Evidence & Value
Ramon Hernandez Vecino, Head Of Real World Evidence Data And Analytics Engagement Lead Randd, Sanofi
Chair’s remarks
Pricing and Market Access & Government Affairs
Anne Marciniak, Head Of Market Access, Europe, Aimmune
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Chair’s remarks
Managed Entry Agreements, HTA & Advanced Therapies
Adam Heathfield, Senior Director Of Global Health And Value Innovation Centre, Pfizer Ltd
Developing capabilities to support effective evaluation of data
Evidence & Value
Sue Naeyaert, Advisor, Independent
Exploring challenges and opportunities across South Africa on achieving new affordable strategies for Universal Health Coverage
Pricing and Market Access & Government Affairs
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
The incentives’ review by the EU Commission and its implication on OMPs
Rare Diseases, Big Data, Diagnostics & Digital
Ana Palma, Senior Director Global Hta And Patient Access Lead, Sobi
A manufacturer’s move to patient-centricity
Managed Entry Agreements, HTA & Advanced Therapies
Scott Doyle, Senior Director, Gheor, Astellas
Develop robust RWE Analytics Capability to enable rapid evidence generation
Evidence & Value
Yonghua Jing, Director, Real World Evidence & Analytics, Health Economics & Outcomes Research, AbbVie
New HTA - regulations for Orphan drugs in Germany
Rare Diseases, Big Data, Diagnostics & Digital
Antje Behring, Acting Head, Federal Joint Committee
Perspectives from the Alliance for Regenerative Medicine: improving access to cell and gene therapies
Managed Entry Agreements, HTA & Advanced Therapies
Interview: Achieving greater collaboration with HTAs: Insights from EUnetHTA
Pricing and Market Access & Government Affairs
Marcus Guardian, Chief Operating Officer, EUnetHTA
The role of real-world evidence in establishing optimal access for an orphan disease
Evidence & Value
Anindita Sinha, Pipeline Lead, US Market Access, Immunology, Boehringer Ingelheim
Where do we go from here - bridging the gap from regulatory approval to market access using MoCA
Rare Diseases, Big Data, Diagnostics & Digital
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Looking at Value for Advanced Therapies in Quebec
Managed Entry Agreements, HTA & Advanced Therapies
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Chair’s remarks
Evidence & Value
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Chair’s remarks
Pricing and Market Access & Government Affairs
Hanadi Nahas, Chairman And General Manager, Access Core
Chair’s remarks
Rare Diseases, Big Data, Diagnostics & Digital
Sheela Upadhyaya, Rare Disease Expert, National Institute for Health and Care Excellence
Chair’s remarks
Managed Entry Agreements, HTA & Advanced Therapies
Real-world evidence and the 2020 NICE Methods Update
Evidence & Value
Micah Rose, Senior Scientific Adviser - Health Economic Modelling, NICE Scientific Advice
Drivers of preference for prefilled syringes for anaesthesia/ICU drugs in British, French and German hospitals
Pricing and Market Access & Government Affairs
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Working with stakeholders to improve access to rare disease treatments
Rare Diseases, Big Data, Diagnostics & Digital
Natasa Zibelnik, Global Head Of Market Access, EUSA Pharma
Using RWE to support innovative contracting
Evidence & Value
Lotte Steuten, Vice President And Head Of Consulting, Office of Health Economics
The role of pharmacy in Patient Support Programs
Pricing and Market Access & Government Affairs
Andrew Lane, Chair, National Pharmacy Association
Achieving greater collaboration to improve access to rare disease treatments and to improve outcomes for patients
Rare Diseases, Big Data, Diagnostics & Digital
Kevin Loth, Former Vice President, Corporate Affairs And Policy, Worldwide Markets, Celgene
Key considerations of the health technology assessment of CAR-Ts in Europe
Managed Entry Agreements, HTA & Advanced Therapies
Renske Ten Ham, Researcher, Utrecht University
Registries for orphan drugs in the German AMNOG process
Evidence & Value
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Latest insights on patient support programmes across the Middle East
Pricing and Market Access & Government Affairs
Hanadi Nahas, Chairman And General Manager, Access Core
Bridging the Gap between Payers, Patients & the Advocates Navigating Access to Care
Rare Diseases, Big Data, Diagnostics & Digital
Elizabeth Johnson, Biologics Coordinator, Allergy Partners, P.A.
Access and Pricing considerations for CAR-T
Managed Entry Agreements, HTA & Advanced Therapies
Nuno Prego Ramos, Chief Executive Officer, Cellmabs
last published: 08/Sep/20 16:05 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Marco Rauland, Vice President Global Market Access & Pricing Strategic Planning,
Merck Group
Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK's Market Access practice. Before that Marco was the global head of the...
Nico Mros, Chief Operating Officer,
Lyfegen HealthTech AG
Lyfegen’s existence is driven by the untiring strive to help patients access value-adding therapies to improve health outcomes. To do so, we work together with all healthcare stakeholders to accelerate & facilitate access to these therapies by providing innovative and scalable technology...
Marco Rauland, Vice President Global Market Access & Pricing Strategic Planning,
Merck Group
Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK's Market Access practice. Before that Marco was the global head of the...
Nadeem Ashraf, Head Of CardioMetabolism, UK & Ireland,
Boehringer Ingelheim
Nadeem is a Pharma industry medic with 17 years of combined commercial, digital and medical affairs experience; currently working as medical advisor for Lilly Diabetes in the UK. Nadeem is also a student of Health Economics & Health Policy and is passionate about digital health, internet of...
Wills Hughes-Wilson, Head Of Patient Access And Commercial Planning,
Mereo BioPharma
Wills Hughes-Wilson is Head of Patient Access & Commercial Planning at Mereo Biopharma and a member of the company’s executive leadership team. She joined Mereo in February 2018 with responsibility for leading and optimising the company’s patient access and commercialisation strategies. ...
Bruno DE PAZ, Chief Executive Officer,
Prioritis Market Access
Prioritis is a market access consultancy company specialized in pricing and reimbursement strategies for pharmaceutical, biotechnology and medical devices. Aware of economic issues, Prioritis is the true and valuable partner, advising its clients at all stages of product development and...
Yannick Loonus, Chief Sales Officer,
Semalytix GmbH
Dr. Yannick Loonus is the CSO of Semalytix and responsible for all activities related to business development, customer care, and marketing. He is passionate about the latest advances in information science, artificial intelligence, and entrepreneurship. Before joining Semalytix, Yannick spent five ...
Adam Kundzewicz, Senior Global Payer Strategy Manager, Head Of Pricing,
Boehringer Ingelheim Pharma GmbH & Co. KG
Adam is a Senior Global Payer Strategy Manager working in oncology pipeline at Boehringer Ingelheim. He is managing global pricing and market access strategies for the oncology portfolio and driving the development of innovative market access approaches and payment schemes. Since September 2015 ...
David Thompson, Senior Vice President, Head Of Thought Leadership, Real World And Late Phase Research,
Syneos Health
• David is a health economist with 30+ years of experience in the health economics arena. Prior to joining Syneos Health, he held leadership positions at Quintiles (2012-2016), i3 Innovus/OptumInsight (2000-2012) and PAI (1988-2000). He is also a current committee member of the Clinical...
Sandra Garitonandía, Business Development Manager,
Vistex
Life Sciences passionate and specialized in Revenue Management for PharmaBackground in medical and business educational studiesBroad international experience in different positions in business and IT in Life SciencesSpecialization area is where business processes meet the IT systems and how to...
Rosemary Jose, Director And Commercial Lead, Strategic Market Access,
Pharmerit International
Rosemary Jose is Director and Commercial Lead for the Strategic Market Access Center of Excellence, and is based out of the Rotterdam office, the Netherlands. Her main areas of focus are business development, payer value communication, payer/HTA landscape assessments, recent trends in EUnetHTA and...
Alison Howell, Director,
Covance
Alison is a Director in Covance’s Market Access Consulting group and is based in London. Alison has over 15 years of experience of strategic and tactical value demonstration projects, ranging from market access strategy and value message development, to delivery of communication tools of varying...
Wills Hughes-Wilson, Head Of Patient Access And Commercial Planning,
Mereo BioPharma
Wills Hughes-Wilson is Head of Patient Access & Commercial Planning at Mereo Biopharma and a member of the company’s executive leadership team. She joined Mereo in February 2018 with responsibility for leading and optimising the company’s patient access and commercialisation strategies. ...
Erwin De Cock, Principal, Late Stage,
Syneos Health
Erwin De Cock, MSc is a health economist and real-world data scientist with over 19 years of biopharmaceutical consultancy experience. Erwin joined Syneos Health in 2017. Prior to this, he held various roles at United BioSource Corporation, a CRO specialized in late stage research, where he was...
Sofie Alverlind, Project Manager,
Swedish Association of Local Authorities and Regions
Sofie Alverlind, MSc Pharm, is an officer and project manager at the Swedish Association of Local Authorities and Regions. She is the coordinator of the New Therapies Council, an expert committee giving the Swedish county councils recommendations on the use of new medicines and had a key role in...
Dylan Lamb-Palmer, Manager, Pricing and Data Analytics,
PDCI Market Access Inc
Dylan Lamb-Palmer is a Manager of Pricing and Data Analytics at PDCI. Dylan joined PDCI full time in 2013 after several years as a summer student with PDCI.Working with the PDCI’s Health Economics (HE) team and HE partners, Dylan develops health economic models...
Yannick Loonus, Chief Sales Officer,
Semalytix GmbH
Dr. Yannick Loonus is the CSO of Semalytix and responsible for all activities related to business development, customer care, and marketing. He is passionate about the latest advances in information science, artificial intelligence, and entrepreneurship. Before joining Semalytix, Yannick spent five ...
Paolo Morgese, Director, Market Access And Member Relations,
Alliance for Regenerative Medicine
Paolo is a healthcare investment and market access professional with more than 15 years of experience in both assessing and supporting access to innovative healthcare technologies. Since 2017, Paolo is EU Director Market Access and Members Relations at the Alliance for Regenerative Medicine (ARM)...
Paolo Morgese, Director, Market Access And Member Relations,
Alliance for Regenerative Medicine
Paolo is a healthcare investment and market access professional with more than 15 years of experience in both assessing and supporting access to innovative healthcare technologies. Since 2017, Paolo is EU Director Market Access and Members Relations at the Alliance for Regenerative Medicine (ARM)...
